2014年3月,FDA批准Paladin Therapeutics的抗感染药米替福新(Impavido)用于治疗热带疾病利什曼病。本病是一种由利什曼虫引起的疾病,其可通过沙和沙蝇传播给人类,主要发生于生活在热带和亚热带的人群中。本品为口服抗感染药,获批用于内脏利什曼病、皮肤利什曼病和黏膜利什曼病等3种利什曼病的治疗。本品适用于12岁及以上患者。本品的安全性和有效性已获得4项临床研究认证。研究显示,547例患者接受米替福新治疗,183例患者接受对照 In March 2014, the FDA approved Paladin Therapeutics’ anti-infective drug Impavido for the treatment of tropical disease leishmaniasis. The disease is a disease caused by Leishmaniasis that can be transmitted to humans through sand and sand flies, primarily in people living in the tropics and subtropics. This product is oral anti-infectives, approved for the treatment of visceral leishmaniasis, cutaneous leishmaniasis and mucosal leishmaniasis 3 leishmaniasis treatment. This product is suitable for patients aged 12 and over. This product has been the safety and effectiveness of four clinical studies certification. The study showed 547 patients receiving new treatment with mirtin and 183 patients receiving control